heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomisedcontrolled phase 3 trial in Russia”. The Lancet. doi:10.1016/s0140-6736(21)00234-8
vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomisedcontrolled trials in Brazil, South Africa, and the UK - The Lancet”. 9 December